iTeos Therapeutics appoints Ann D. Rhoads to board of administrators

Cambridge, MA and Gosselies, Belgium – June 1, 2020 – iTeos Therapeutics, a clinical-stage biopharmaceutical firm pioneering the invention and growth of a brand new era of extremely differentiated immuno-oncology therapies for sufferers, at the moment introduced the appointment of Ann D. Rhoads to its board of ‘administration. Ms. Rhoads brings over 25 years of company and monetary experience within the life sciences and well being sector.

“I’m delighted to welcome Ann to our Board of Administrators at a transformative time within the firm’s historical past. Having lately accomplished our $ 125 million Collection B-2 financing with a robust syndicate of traders, we at the moment are poised to advance the medical growth of our two extremely modern oncology pipeline packages, an A2A adenosine receptor antagonist, EOS-850, and an anti-TIGIT antibody, EOS -448, ” mentioned David Hallal, Chairman of the Board of Administrators of iTeos Therapeutics. “Ann is a acknowledged chief and brings perfect experience to our Board of Administrators. I look ahead to working together with her and our different directors to collaborate with the management group as they search to stimulate the event of therapies that may rework the lives of sufferers. affected by most cancers. “

“Ann has a formidable observe report in govt administration in our trade, significantly within the space of ​​immuno-oncology; his huge expertise will probably be instrumental to us as we proceed our development path. I’m delighted to welcome him to the board and to benefit from his experience ”, added Michel Detheux, PhD, President and CEO of iTeos Therapeutics.

Ms. Rhoads most lately served as Chief Monetary Officer of Forty Seven, Inc., a clinical-stage immuno-oncology firm, from 2018 till its sale to Gilead in 2020. Throughout her tenure at Forty Seven, Inc. ., it carried out an preliminary public providing and two subsequent fairness financings. From 2010 to early 2017, she was Government Vice President and Chief Monetary Officer of Zogenix, Inc. the place she oversaw all areas of economic administration together with the corporate’s preliminary public providing and financings. by subsequent shares and borrowing. Previous to becoming a member of Zogenix in 2010, Ms. Rhoads was Senior Vice President and Chief Monetary Officer of healthcare enchancment firm Premier, Inc. Ms. Rhoads started her profession as an funding skilled with Merrill Lynch and the Sprout group, the enterprise capital subsidiary of Donaldson, Lufkin & Jenrette (now a part of Credit score Suisse). Ms. Rhoads holds an MBA from Harvard Enterprise College and a BS in Enterprise Administration with a spotlight in Finance from the College of Arkansas.

“ITeos is advancing two modern candidates in immunotherapy within the clinic, each of that are very totally different from different packages in medical growth”, commented Ann Rhoads. “I look ahead to working with the administration group and the board of administrators to assist iTeos advance its monetary and enterprise objectives utilizing the information and expertise I’ve gained throughout my profession.”

About iTeos Therapeutics

iTeos is a clinical-stage biopharmaceutical firm pioneering the invention and growth of a brand new era of extremely differentiated immuno-oncology therapies for sufferers. iTeos is leveraging its in-depth understanding of the tumor microenvironment and immunosuppressive pathways to design new product candidates with the objective of bettering the medical advantages of oncology therapies. The modern pipeline consists of two clinical-stage packages concentrating on novel validated immuno-oncology pathways designed to construct on earlier studying within the subject to have differentiated pharmacological and medical profiles. Essentially the most superior product candidate, EOS-850, is designed as a extremely selective small molecule antagonist of the adenosine A2a receptor within the adenosine triphosphate adenosine pathway, a key think about immunosuppression within the tumor microenvironment in a variety of tumors. EOS-850 is being studied in an open-label Part 1 / 2a medical trial in grownup sufferers with superior stable tumors and inspiring preliminary monotherapy exercise has been noticed within the dose-escalation portion of take a look at. The lead antibody candidate, EOS-448, is a TIGIT antagonist, or T cell immunoreceptor with Ig and ITIM domains, a checkpoint that performs a task in inhibitory and stimulating pathways of the immune system. EOS-448 was additionally designed to interact the gamma Fc receptor, or FcgR, to advertise antibody-dependent mobile cytotoxicity, or ADCC, exercise, together with the elimination of tumor infiltrating regulatory T cells, or Tregs. An open-label section 1 / 2a medical trial of EOS-448 has lately been initiated in grownup sufferers with superior stable tumors. The corporate lately closed a $ 125 million Collection B-2 financing from giant biotech traders together with RA Capital, Boxer Capital, MPM Capital, Janus Henderson Advisors, RTW Investments, Invus, HBM Companions, Fund +, Vives II, SRIW and SFPI. iTeos Therapeutics is headquartered in Cambridge, MA with a analysis middle in Gosselies, Belgium. For extra info, please go to www.iteostherapeutics.com.

For extra info, please contact:

Michel Detheux, CEO
iTeos Therapeutics Inc
[email protected]

Amber Fennell, Paul Kidwell
Strategic communications of the Consilium
+44 203 709 5700
[email protected]

Sarah McCabe and Zofia Mita
Stern Investor Relations, Inc.
+ 1 212 362 1200
[email protected]